UK Branded Medicines Pricing & Access Deal - Hits & Misses To Date
Industry Concerned Over Market Access As Five-Year Deal Reaches Half-Way Mark
Industry has paid millions of pounds under the ongoing UK Voluntary Scheme on Branded Medicines Pricing and Access but there are concerns over poor progress with other commitments that were promised under the scheme for managing branded medicine spend by the National Health Service.
You may also be interested in...
The UK drug regulator, the MHRA, has approved its first product under Project Orbis, the US-led international regulatory collaboration scheme it joined four months ago to speed up access to promising cancer medicines.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
The COVID-19 pandemic will have a lasting impact on the world, including on Health Technology Assessment (HTA). The debate on how HTA should change as a result of COVID-19 is gaining momentum, but could a wider approach to value and a higher threshold be a false dawn?